Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 216

Results For "IMI"

4535 News Found

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Drug Approval | January 26, 2024

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia


Strides receives USFDA approval for Pregabalin Capsules
Drug Approval | January 26, 2024

Strides receives USFDA approval for Pregabalin Capsules

The Pregabalin capsules has a market size of ~US$248 mn per IQVIA


Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
News | January 26, 2024

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)


Shilpa Medicare directed to to pay damage to Celltrion
News | January 25, 2024

Shilpa Medicare directed to to pay damage to Celltrion

The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement


Health Minister Mandaviya inaugurates super specialty block at GSVM Medical College in UP
Healthcare | January 25, 2024

Health Minister Mandaviya inaugurates super specialty block at GSVM Medical College in UP

Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur


Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
News | January 25, 2024

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023


Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
News | January 25, 2024

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023


Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
News | January 23, 2024

Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr

Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023


EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
Drug Approval | January 23, 2024

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023